About this toolkit

Cancer is the primary causes of death in the UK and one of the highest causes of death around Europe. In comparison to other European countries, the UK is lagging behind in terms of care and treatment outcomes for its cancer patients. What can we learn from other European countries’ cancer care outcomes?

This interactive toolkit brings together data from the Institute for Health Economics' Comparator Report on Patients Access to Cancer Medicines Revisited - a UK Perspective on the UK’s incidence, mortality, survival, spending and medicines uptake for the following cancer types in comparison to Europe:

Funding to support the development of this toolkit came from an unrestricted grant from the following ABPI member companies: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eisai, GSK, Janssen, Merck Sharp and Dohme, Napp, Novartis, Pfizer and Takeda.

About the ABPI

The Association of the British Pharmaceutical Industry (ABPI) is a membership organisation of innovative research-based biopharmaceutical companies in the UK, whose research and investments bring life-saving and life-enhancing medicines to patients.

Thousands of cancer patients are living longer and better quality lives thanks to new innovative medicines developed by the ABPI’s members. However, cancer patient outcomes in the UK are still lagging behind those of many other European countries.

In order to help understand the scale of the challenge facing people with cancer in the UK in comparison to the rest of Europe, the ABPI has developed this toolkit, which includes the most up to date available data on cancer incidence, survival, mortality, spending and medicines uptake for a selected number of cancers across Europe.

The ABPI is keen to ensure that the current system tackles the real issues that people living with cancer face and is able to respond to the future of cancer care.

To this end, it is calling for a concerted effort from policy makers, patient groups and clinicians to improve cancer patients’ access to innovative treatments.

How to use this toolkit

This interactive toolkit allows you to compare cancer outcomes by incidence, survival, mortality, spending and medicines uptake or according to cancer type.

Each cancer-specific section can be accessed by clicking the relevant button at the top of the page.

Hovering over the bars in each graph will show the data value reported.

Below each graph, there are three buttons. “EURO27” shows data across all European countries. “EURO5” shows how the UK compares with France, Germany, Italy and Spain. The graph also shows the EURO4 average, ie the France, Germany, Italy and Spain average. The “Data” button allows you to download the full data set.

The graphs in the ‘Medicines’ section are interactive. Each country on the graph can be selected and de-selected by clicking on the country’s name at the bottom of the graph.

Countries’ names on graphs are abbreviated. A full list of all country abbreviations can be found below:

AbbreviationCountry
ATAustria
BEBelgium
BGBulgaria
HRCroatia
CHSwitzerland
CYCyprus
CZCzech Republic
DKDenmark
EEEstonia
FIFinland
FRFrance
DEGermany
ELGreece
HUHungary
IEIreland
ISIceland
ITItaly
LVLatvia
LTLithuania
LULuxembourg
MTMalta
NLNetherlands
NONorway
PLPoland
PTPortugal
RORomania
SKSlovakia
SISlovenia
ESSpain
SESweden
UKUK
EU-27EU-27